Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GKL-006 injection plus TACE versus TACE alone for unresectable hepatocellular carcinoma
CTR20253777Phase 2Active
- Sponsor
- Gene-Qi-Ming
- Start
- Nov 2025
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of GKL-006 in hepatocellular carcinoma (HCC), sponsored by Gene-Qi-Ming. Started Nov 2025; status: active.
02
Drugs
GKL-006
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20253777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253777.